DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 19:30:42 04/06/2024 BST | ||
| 413.5 EUR | +0.81% |
|
| Current month | +2.64% | ||
| 1 month | +11.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 413.5 | +0.81% |
| 03/06/24 | 410.1 | +1.81% |
| 31/05/24 | 402.8 | +1.66% |
| 30/05/24 | 396.3 | -0.46% |
| 29/05/24 | 398.1 | -2.05% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 07:30 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME82BH |
| ISIN | DE000ME82BH3 |
| Date issued | 01/02/2024 |
| Maturity | 20/12/2024 (199 Days) |
| Parity | 1 : 1 |
| Emission price | 395 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 413.5 € |
|---|---|
| Lowest since issue | 359.2 € |
| Spread | 1.02 € |
| Spread % | 0.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat